BACKGROUND: Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Clonazepam, a benzodiazepine, is an established antiepileptic drug, but its place in the treatment of neuropathic pain is unclear. OBJECTIVES: To assess the analgesic efficacy and adverse effects of the antiepileptic drug clonazepam in neuropathic pain and fibromyalgia. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 2). MEDLINE, and EMBASE to 28 February 2012, together with reference lists of retrieved papers and reviews, and ClinicalTrials.gov. SELECTION CRITERIA: We planned to include randomised, double-blind studies of eight weeks duration or longer, comparing clonazepam with placebo or another active treatment in chronic neuropathic pain or fibromyalgia. DATA COLLECTION AND ANALYSIS: Two review authors would independently extract data for efficacy and adverse events, and examine issues of study quality. MAIN RESULTS: We did not identify any studies that satisfied the inclusion criteria. AUTHORS' CONCLUSIONS: This review uncovered no evidence of sufficient quality to support the use of clonazepam in chronic neuropathic pain or fibromyalgia.
BACKGROUND: Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Clonazepam, a benzodiazepine, is an established antiepileptic drug, but its place in the treatment of neuropathic pain is unclear. OBJECTIVES: To assess the analgesic efficacy and adverse effects of the antiepileptic drug clonazepam in neuropathic pain and fibromyalgia. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 2). MEDLINE, and EMBASE to 28 February 2012, together with reference lists of retrieved papers and reviews, and ClinicalTrials.gov. SELECTION CRITERIA: We planned to include randomised, double-blind studies of eight weeks duration or longer, comparing clonazepam with placebo or another active treatment in chronic neuropathic pain or fibromyalgia. DATA COLLECTION AND ANALYSIS: Two review authors would independently extract data for efficacy and adverse events, and examine issues of study quality. MAIN RESULTS: We did not identify any studies that satisfied the inclusion criteria. AUTHORS' CONCLUSIONS: This review uncovered no evidence of sufficient quality to support the use of clonazepam in chronic neuropathic pain or fibromyalgia.
Authors: Christelle Gremeau-Richard; Alain Woda; Marie Louise Navez; Nadine Attal; Didier Bouhassira; Marie Claude Gagnieu; Jean François Laluque; Pascale Picard; Paul Pionchon; Stéphanie Tubert Journal: Pain Date: 2004-03 Impact factor: 6.961
Authors: B Gustorff; T Dorner; R Likar; W Grisold; K Lawrence; F Schwarz; A Rieder Journal: Acta Anaesthesiol Scand Date: 2007-11-01 Impact factor: 2.105
Authors: Michael H Andreae; George M Carter; Naum Shaparin; Kathryn Suslov; Ronald J Ellis; Mark A Ware; Donald I Abrams; Hannah Prasad; Barth Wilsey; Debbie Indyk; Matthew Johnson; Henry S Sacks Journal: J Pain Date: 2015-09-09 Impact factor: 5.820
Authors: Philip J Wiffen; Sheena Derry; R Andrew Moore; Dominic Aldington; Peter Cole; Andrew S C Rice; Michael P T Lunn; Katri Hamunen; Maija Haanpaa; Eija A Kalso Journal: Cochrane Database Syst Rev Date: 2013-11-11
Authors: Pascal H Vuilleumier; Marie Besson; Jules Desmeules; Lars Arendt-Nielsen; Michele Curatolo Journal: PLoS One Date: 2013-03-15 Impact factor: 3.240